低风险胆囊切除术中预防性使用抗菌药物与更少手术部位感染相关:瑞士全国队列研究
该全国队列研究纳入2009至2020年瑞士66家医院44,682例接受胆囊切除术的成人患者中12,521例符合低风险标准者,评估预防性使用抗菌药物与不使用的SSI风险差异。结果显示SSI总体发生率为1.1%,预防性用药与更低的SSI率相关(调整OR 0.50,95%CI 0.35-0.70,P<0.001),每预防1例SSI需治疗100例。
要点
- 低风险胆囊切除术SSI总体发生率为1.1%。
- 预防性使用抗菌药物与SSI风险降低50%相关。
- 每预防1例SSI需治疗100例低风险胆囊切除术患者。
核心结论
- 低风险胆囊切除术中预防性使用抗菌药物与更低的SSI率相关,调整OR为0.50(95%CI 0.35-0.70,P<0.001)。
- 低风险胆囊切除术患者可能从常规预防性使用抗菌药物中获益。
研究设计与样本
- 全国性队列研究,纳入2009年1月至2020年12月瑞士66家医院经Swissnoso SSI监测系统记录的成人低风险胆囊切除术患者。
- 低风险胆囊切除术定义为择期内镜手术、年龄<70岁、无活动性胆囊炎、ASA评分<3、手术时间<120分钟且无异物植入。
- 暴露定义为切皮前120分钟内给予头孢呋辛或头孢唑林±甲硝唑,对照为未预防性使用抗菌药物。
- 主要结局为至术后第30天发生SSI,采用逻辑回归模型调整机构、患者和围术期变量。
- 44,682例接受监测的成人胆囊切除术患者中12,521例符合纳入标准。
主要发现
- 12,521例纳入患者中8726例为女性(69.7%),中位年龄49.0岁(四分位距38.1-58.2)。
- 143例患者发生SSI,总体发生率为1.1%。
- 9269例(74.0%)接受了预防性使用抗菌药物。
- 预防性使用抗菌药物与更低的SSI率相关,调整OR为0.50(95%CI 0.35-0.70,P<0.001)。
- 预防1例SSI所需的治疗人数为100。
临床怎么用
- 对于符合低风险标准的胆囊切除术患者,可考虑常规预防性使用抗菌药物以降低SSI风险。
- 低风险胆囊切除术的SSI总体发生率较低(1.1%),需结合获益与抗菌药物管理原则个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether administration of surgical antimicrobial prophylaxis (SAP) versus absence of SAP is associated with a decreased risk of surgical site infections (SSIs) after low-risk cholecystectomies (LR-CCEs). BACKGROUND: Current guidelines do not recommend routine SAP administration before LR-CCE. METHODS: This cohort study included adult patients who underwent LR-CCE and were documented by the Swissnoso SSI surveillance system between January 2009 and December 2020 at 66 Swiss hospitals. LR-CCE was specified as elective endoscopic surgery, age <70, no active cholecystitis, ASA score <3, operating time <120 minutes without implantation of foreign material. Exposure was defined as the administration of cefuroxime or cefazoline ± metronidazole within 120 minutes before incision versus no SAP administration. Our main outcome was the occurrence of SSI until day 30. Logistic regression models were used to adjust for institutional, patient, and perioperative variables. RESULTS: Of 44,682 surveilled adult patients undergoing cholecystectomy, 12,521 [8726 women (69.7%); median (interquartile range) age, 49.0 (38.1-58.2) years] fulfilled the inclusion criteria. SSI was identified in 143 patients (1.1%). SAP was administered in 9269 patients (74.0%) and was associated with a lower SSI rate (adjusted odds ratio, 0.50; 95% CI, 0.35-0.70; P < 0.001). The number needed to treat to prevent 1 SSI episode is 100. CONCLUSIONS: The overall LR-CCE SSI rate was 1.1%. SAP was associated with a 50% lower overall SSI rate. Patients undergoing LR-CCE may benefit from routine SAP.
引用
- Florinett L, Widmer A, Troillet N, et al. Surgical Antimicrobial Prophylaxis in Low-risk Cholecystectomies is Associated With Fewer Surgical Site Infections: Nationwide Cohort Study in Switzerland. Ann Surg. 2024. PMID: 38881461. doi:10.1097/SLA.0000000000006396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。